S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.03
$1.03
50-Day Range
$0.94
$1.03
52-Week Range
$0.32
$1.57
Volume
N/A
Average Volume
1.93 million shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.44

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
136.7% Upside
$2.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.14) to $0.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

713th out of 968 stocks

Pharmaceutical Preparations Industry

319th out of 440 stocks


SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.


SPPI Stock News Headlines

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
SPPI - Spectrum Pharmaceuticals, Inc.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Q1 2023 Assertio Holdings Inc Earnings Call
Expert Ratings for Spectrum Pharma
JMP Securities downgrades Spectrum Pharmaceuticals (SPPI) to a Hold
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2021
Today
9/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
86
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$2.44
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$0.75
Forecasted Upside/Downside
+136.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-75,400,000.00
Pretax Margin
-263.04%

Debt

Sales & Book Value

Annual Sales
$10.11 million
Book Value
$0.15 per share

Miscellaneous

Free Float
199,704,000
Market Cap
$211.41 million
Optionable
Optionable
Beta
2.15

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Thomas J. RigaMr. Thomas J. Riga (Age 48)
    Pres, CEO & Director
    Comp: $1.07M
  • Ms. Nora E. Brennan (Age 54)
    Exec. VP & CFO
    Comp: $46.25k
  • Mr. Keith M. McGahan J.D.Mr. Keith M. McGahan J.D. (Age 47)
    L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $948.26k
  • Mr. Michael A. Grabow
    Exec. VP & Chief Bus. Officer
  • Dr. Lyndah K. Dreiling M.B.A.
    M.D., Sr. VP of Clinical Devel.













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares.
View SPPI analyst ratings
or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 12 month price objectives for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they predict the company's share price to reach $2.44 in the next year. This suggests a possible upside of 136.7% from the stock's current price.
View analysts price targets for SPPI
or view top-rated stocks among Wall Street analysts.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. During the same period in the prior year, the firm earned ($0.37) EPS.

What ETF holds Spectrum Pharmaceuticals' stock ?

IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Kennedy Capital Management LLC (2.38%), BlackRock Inc. (1.70%), Acadian Asset Management LLC (1.42%), Ergoteles LLC (1.14%), Geode Capital Management LLC (0.87%) and Renaissance Technologies LLC (0.69%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer and Thomas J Riga.
View institutional ownership trends
.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $1.03.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $211.41 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -